Eton Pharmaceuticals Stock Total Asset
| ETON Stock | USD 14.39 0.26 1.84% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Eton Pharmaceuticals' long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Total Assets | 76.1 M | 79.9 M | |
| Intangibles To Total Assets | 0.46 | 0.48 |
Eton | Total Asset | Build AI portfolio with Eton Stock |
Eton Pharmaceuticals Company Total Asset Analysis
Eton Pharmaceuticals' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Eton Pharmaceuticals Total Asset | 76.12 M |
Most of Eton Pharmaceuticals' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eton Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Eton Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Eton Pharmaceuticals is extremely important. It helps to project a fair market value of Eton Stock properly, considering its historical fundamentals such as Total Asset. Since Eton Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eton Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eton Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Eton Total Asset Historical Pattern
Today, most investors in Eton Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eton Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Eton Pharmaceuticals total asset as a starting point in their analysis.
Eton Pharmaceuticals Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Eton Total Assets
Total Assets |
|
Based on the latest financial disclosure, Eton Pharmaceuticals has a Total Asset of 76.12 M. This is 98.99% lower than that of the Pharmaceuticals sector and 96.15% lower than that of the Health Care industry. The total asset for all United States stocks is 99.74% higher than that of the company.
Eton Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eton Pharmaceuticals' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eton Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eton Pharmaceuticals by comparing valuation metrics of similar companies.Eton Pharmaceuticals is currently under evaluation in total asset category among its peers.
Eton Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Eton Pharmaceuticals from analyzing Eton Pharmaceuticals' financial statements. These drivers represent accounts that assess Eton Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Eton Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 39.3M | 127.9M | 170.8M | 70.9M | 63.8M | 82.9M | |
| Enterprise Value | 12.5M | 120.4M | 156.7M | 61.1M | 55.0M | 71.5M |
Eton Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eton Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eton Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Eton Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Eton Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Eton Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eton Pharmaceuticals' value.| Shares | Geode Capital Management, Llc | 2025-03-31 | 298.2 K | Renaissance Technologies Corp | 2025-03-31 | 274 K | Aristides Capital Llc | 2025-03-31 | 241.6 K | Connor Clark & Lunn Inv Mgmt Ltd | 2025-03-31 | 232.5 K | Thompson, Siegel & Walmsley Llc | 2025-03-31 | 189.9 K | Goldman Sachs Group Inc | 2025-03-31 | 175.2 K | Springbok Capital Management, Llc | 2025-03-31 | 169.4 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 147.3 K | Mink Brook Asset Management Llc | 2025-03-31 | 141.5 K | Opaleye Management Inc | 2025-03-31 | 2.9 M | Ecor1 Capital, Llc | 2025-03-31 | 1.9 M |
Eton Fundamentals
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0202 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.03) % | ||||
| Current Valuation | 391.59 M | ||||
| Shares Outstanding | 26.82 M | ||||
| Shares Owned By Insiders | 4.38 % | ||||
| Shares Owned By Institutions | 53.46 % | ||||
| Number Of Shares Shorted | 3.05 M | ||||
| Price To Earning | (0.94) X | ||||
| Price To Book | 15.50 X | ||||
| Price To Sales | 7.84 X | ||||
| Revenue | 39.01 M | ||||
| Gross Profit | 28.27 M | ||||
| EBITDA | (1.45 M) | ||||
| Net Income | (3.82 M) | ||||
| Cash And Equivalents | 17.05 M | ||||
| Cash Per Share | 0.67 X | ||||
| Total Debt | 29.92 M | ||||
| Debt To Equity | 0.48 % | ||||
| Current Ratio | 5.19 X | ||||
| Book Value Per Share | 0.91 X | ||||
| Cash Flow From Operations | 969 K | ||||
| Short Ratio | 4.76 X | ||||
| Earnings Per Share | (0.18) X | ||||
| Target Price | 29.67 | ||||
| Number Of Employees | 31 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 378.93 M | ||||
| Total Asset | 76.12 M | ||||
| Retained Earnings | (107.89 M) | ||||
| Working Capital | 21.07 M | ||||
| Current Asset | 24.61 M | ||||
| Current Liabilities | 1.81 M | ||||
| Net Asset | 76.12 M |
About Eton Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eton Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eton Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eton Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Eton Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eton Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eton Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eton Stock
| 0.7 | VERV | Verve Therapeutics Earnings Call This Week | PairCorr |
| 0.6 | A | Agilent Technologies Earnings Call Today | PairCorr |
| 0.59 | VNDA | Vanda Pharmaceuticals | PairCorr |
| 0.55 | VANI | Vivani Medical | PairCorr |
| 0.51 | VIGL | Vigil Neuroscience | PairCorr |
The ability to find closely correlated positions to Eton Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eton Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eton Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eton Pharmaceuticals to buy it.
The correlation of Eton Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eton Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eton Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eton Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Eton Pharmaceuticals Piotroski F Score and Eton Pharmaceuticals Altman Z Score analysis. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share (0.18) | Revenue Per Share | Quarterly Revenue Growth 1.169 | Return On Assets |
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.